Emilia Slabinski, PA-C | |
82 New Park Ave, North Franklin, CT 06254-1807 | |
(860) 889-7345 | |
Not Available |
Full Name | Emilia Slabinski |
---|---|
Gender | Female |
Speciality | Physician Assistant - Surgical |
Location | 82 New Park Ave, North Franklin, Connecticut |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1225804263 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207XS0117X | Orthopaedic Surgery - Orthopaedic Surgery Of The Spine | 6388 (Connecticut) | Secondary |
363AS0400X | Physician Assistant - Surgical | 6388 (Connecticut) | Primary |
Mailing Address | Practice Location Address |
---|---|
Emilia Slabinski, PA-C 1150 S Main St Apt 111, Middletown, CT 06457-5039 Ph: (908) 907-7822 | Emilia Slabinski, PA-C 82 New Park Ave, North Franklin, CT 06254-1807 Ph: (860) 889-7345 |
News Archive
The Medical Research Council (MRC) and the National Institute for Health Research (NIHR) have announced a new joint arrangement for clinical trials. The initiative forms a key part of the developing MRC- NIHR joint strategy for translational research.
Migraines affect millions of people worldwide, often lasting days and severely disrupting lives. More than simply super-intense headaches, some migraines actually result from pathological excitation of neurons in the brain.
UC Irvine and French researchers have identified a central switch responsible for the transformation of healthy brain cells into epileptic ones, opening the way to both treat and prevent temporal lobe epilepsy.
A study by global health service company Cigna Corporation (NYSE: CI) shows that individuals whose medical, behavioral and pharmacy health benefits are connected and administered by Cigna are more engaged in their health and well-being than those whose benefits are not fully integrated across medical, behavioral and pharmacy.
BioTime, Inc. today announced a material transfer agreement (MTA) with the University of California (UC) system to make five research-grade human embryonic stem (hES) cell lines available to UC system researchers. These lines are genetically identical to a bank of GMP-compliant hES cell lines that will be made available to California-based researchers under a recent agreement between BioTime and the California Institute for Regenerative Medicine (CIRM).
› Verified 4 days ago